|Bid||4.38 x 1200|
|Ask||4.47 x 27000|
|Day's Range||4.0200 - 4.5200|
|52 Week Range||0.3880 - 21.8000|
|Beta (3Y Monthly)||2.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.00|
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Joanne T. Beck, Ph.D., to its Board of Directors. Dr. Beck has more than 25 years of pharmaceutical development and operations experience and is currently the Executive Vice President, Global Pharmaceutical Development and Operations at Celgene. “Joanne brings deep knowledge of pharmaceutical development and operations to Catabasis, and we are excited to have her join our board of directors,” said Ken Bate, Chairman of Catabasis’ Board of Directors.
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,000,000 units at a public offering price of $5.00 per unit. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock for a total of 4,000,000 shares of common stock and warrants to purchase 2,000,000 shares of common stock. Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 5) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Array ...
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering.
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Jill Milne has been the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) since 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Catabasis Pharmaceuticals, Inc. (CATB) has been struggling lately, but the selling pressure may be coming to an end soon.
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Gregg Lapointe to its Board of Directors. Mr. Lapointe has three decades of commercial and financial experience and he is Co-Founder and Chief Executive Officer of Cerium Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases. “Gregg’s broad set of experiences as a leader and a director makes him an excellent addition to our board of directors,” said Ken Bate, co-Chairman of Catabasis’ Board of Directors.
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today shared an update on clinical trial sites in the United States and recent international clinical trial application approvals to perform the Phase 3 PolarisDMD trial for edasalonexent (CAT-1004) in Duchenne muscular dystrophy (DMD). PolarisDMD clinical trial sites in the United States are actively enrolling patients. Top-line results from the Phase 3 PolarisDMD trial are expected in the second quarter of 2020.
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, announced today that it will effect a one-for-ten reverse stock split of its common stock that will be effective on December 28, 2018. The Company's common stock will begin trading on a split-adjusted basis when the market opens on December 31, 2018 under the existing symbol “CATB”. The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Global Market.
Catella Bank S.A, a fully owned subsidiary of Catella AB (publ), has entered an agreement to divest its Card Issuing operations in Luxembourg to Advanzia Bank S.A. as part of the previously announced strategic review. The fixed consideration amounts to approx. SEK 120 Million with an additional earn-out structure with a maximum potential of approx. SEK 240 Million. Divesting the Card Issuing operations in Luxembourg is an important step for Catella in order to exit the consolidated situation due to the extensive regulatory framework and inefficient capital-structure it entails.
SOLNA, Sweden, Dec. 12, 2018 /PRNewswire/ -- Catella Bank S.A., a subsidiary to Catella AB (publ), has entered an agreement to divest 51% of the Wealth Management operations in Sweden to Söderberg & Partners for approximately SEK 36 Million. Catella's ownership in the joint venture structure is expected to generate positive cash flow which is an important part of the value of the transaction. The parties will also enter a strategic partnership.
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced that data from the Phase 1 MoveDMD clinical trial of edasalonexent were published in the Journal of Neuromuscular Diseases, “Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-kB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy”. Edasalonexent was well tolerated in pediatric patients and the data demonstrated that edasalonexent inhibited NF-kB in pediatric patients with Duchenne muscular dystrophy (DMD).
If you’re interested in Catabasis Pharmaceuticals Inc (NASDAQ:CATB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 8 cents. The company's shares closed at 65 cents. A year ago, they were trading at $1.82. _____ This story was generated ...
-- Edasalonexent Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Underway and Starting Enrollment --
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced a collaboration with Pradeep Mammen, MD, FACC, FAHA, founder and Medical Director of the Neuromuscular Cardiomyopathy Clinic at the University of Texas Southwestern (UT Southwestern) Medical Center as well as Co-Director of the National Institute of Health Sponsored UT Southwestern Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center. The mission of this center is to rapidly translate discoveries at the bench into therapies for Duchenne muscular dystrophy (DMD) in the clinic.
Webinar at 1:00pm ET on November 7
The Company Will Host a Conference Call at 8:30am ET